CN Patent

CN112062763B — 羟基吡啶酮并[1,2-b][1,2,5]三氮卓平衍生物及制备和应用

Assigned to Hangzhou Zehnder Medical Technology Co ltd · Expires 2021-11-05 · 5y expired

What this patent protects

本发明公开了羟基吡啶酮并[1,2‑b][1,2,5]三氮卓平衍生物及制备和应用。经实验证明，所述羟基吡啶酮并[1,2‑b][1,2,5]三氮卓平衍生物(通式I)对甲型流感病毒RNA聚合酶活性具有较好抑制作用，可作为流感病毒RNA聚合酶抑制剂，治疗流感病毒引起的感冒。结构通式I如下：

USPTO Abstract

本发明公开了羟基吡啶酮并[1,2‑b][1,2,5]三氮卓平衍生物及制备和应用。经实验证明，所述羟基吡啶酮并[1,2‑b][1,2,5]三氮卓平衍生物(通式I)对甲型流感病毒RNA聚合酶活性具有较好抑制作用，可作为流感病毒RNA聚合酶抑制剂，治疗流感病毒引起的感冒。结构通式I如下：

Drugs covered by this patent

Patent Metadata

Patent number
CN112062763B
Jurisdiction
CN
Classification
—
Expires
2021-11-05
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Zehnder Medical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.